AbbVie snaps eight straight sessions of losses
AbbVie (ABBV) shares snapped eight consecutive sessions of losses as the stock closed up XYZ% at $XYZ. The North ...
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
Last year, pharmaceutical giant AbbVie (NYSE: ABBV) lost patent exclusivity for its biggest cash cow, immunology medicine ...
Zacks.com on MSN22h
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
AbbVie ABBV announced that the European Commission (“EC”) has granted marketing authorization to Elahere (mirvetuximab ...
FiercePharma23h
With new patient resource to close conversation gaps in rheumatic disease, AbbVie makes 'Rheum for Dialogue'
Many patients with rheumatic diseases refrain from telling their doctors about all physical and emotional symptoms they’re ...